Cognitive dysfunction in postmenopausal breast cancer patients on aromatase inhibitors

Expert Review of Anticancer Therapy

Volumn 11, Issue 8, 2011, Pages 1277-1282

  Batalo, Michael ^a   Nagaiah, Govardhanan ^a   Abraham, Jame ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

anastrozole; aromatase inhibitors; chemoprevention trials; cognitive dysfunction; diffusion tensor radiological imaging; estrogen receptor; exemestane; letrozole; neurological functional imaging; neuropsychological testing; postmenopausal; tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FULVESTRANT; LETROZOLE; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; COGNITIVE DEFECT; DIFFUSION TENSOR IMAGING; EXECUTIVE FUNCTION; HORMONE SUBSTITUTION; HUMAN; MEMORY; MENTAL CONCENTRATION; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NONHUMAN; POSTMENOPAUSE; PSYCHOMOTOR PERFORMANCE; REVIEW; VERBAL MEMORY;

AROMATASE INHIBITORS; BREAST NEOPLASMS; COGNITION DISORDERS; FEMALE; HUMANS; POSTMENOPAUSE;

EID: 80052319107     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.112     Document Type: Review

References (26)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365(9472), 1687-1717 (2005).
2. Morse R, Rodgers J, Verrill M, Kendell K. Neuropsychological functioning following systemic treatment in women treated for breast cancer: A review. Eur. J. Cancer 39(16), 2288-2297 (2003).
3. Rapp SR, Espeland MA, Shumaker SA et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial. JAMA 289(20), 2663-2672 (2003).
4. Espeland MA, Rapp SR, Shumaker SA et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291(24), 2959-2968 (2004).
5. Lethaby A, Hogervorst E, Richards M, Yesufu A, Yaffe K. Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database Syst. Rev. 1, CD003122 (2008).
6. Honda K, Sawada H, Kihara T et al. Phosphatidylinositol 3-kinase mediates neuroprotection by estrogen in cultured cortical neurons. J. Neurosci. Res. 60(3), 321-327 (2000).
7. Schilder CM, Seynaeve C, Beex LV et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: Results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J. Clin. Oncol. 28(8), 1294-1300 (2010). Prospective study of cognitive dysfunction in postmenopausal exemestane users that controlled for confounder of prior chemotherapy but not breast cancer.
8. Dietrich J, Monje M, Wefel J, Meyers C. Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist 13(12), 1285-1295 (2008).
9. Jenkins V, Shilling V, Deutsch G et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br. J. Cancer 94(6), 828-834 (2006).
10. Ahles TA, Saykin AJ, McDonald BC et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: Impact of age and cognitive reserve. J. Clin. Oncol. 28(29), 4434-4440 (2010).
11. Abraham J, Haut MW, Moran MT, Filburn S, Lemiuex S, Kuwabara H. Adjuvant chemotherapy for breast cancer: Effects on cerebral white matter seen in diffusion tensor imaging. Clin. Breast Cancer 8(1), 88-91 (2008).
12. Deprez S, Amant F, Yigit R et al. Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Hum. Brain Mapp. 32(3), 480-493 (2011). Prospective study that further demonstrated the utility of neurological functional imaging in evaluating cognitive dysfunction.
13. Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology 13(1), 61-66 (2004).
14. Differential effects of hormonal therapy on cognition in postmenopausal hormone receptor-positive (HR+) breast cancer (BC) patients (pts). Presented at: ASCO 2011. Chicago, IL, USA, 12 March 2011.
15. Jenkins VA, Ambroisine LM, Atkins L, Cuzick J, Howell A, Fallowfield LJ. Effects of anastrozole on cognitive performance in postmenopausal women: A randomised, double-blind chemoprevention trial (IBIS II). Lancet Oncol. 9(10), 953-961 (2008).
16. Jenkins V, Atkins L, Fallowfield L. Does endocrine therapy for the treatment and prevention of breast cancer affect memory and cognition? Eur. J. Cancer 43(9), 1342-1347 (2007). Prospective, chemopreventive study of anastrozole use and cognitive dysfunction that controlled for both breast cancer and prior chemotherapy.
17. Phillips KA, Ribi K, Sun Z et al. Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. Breast 19(5), 388-395 (2010).
18. Phillips KA, Aldridge J, Ribi K et al. Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. Breast Cancer Res. Treat. 126(1), 221-226 (2011).
19. Hermelink K, Henschel V, Untch M, Bauerfeind I, Lux MP, Munzel K. Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: Results of a multicenter, prospective, longitudinal study. Cancer 113(9), 2431-2439 (2008).
20. Bender CM, Sereika SM, Brufsky AM et al. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause 14(6), 995-998 (2007).
21. Schilder CM, Eggens PC, Seynaeve C et al. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: Cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncol. 48(1), 76-85 (2009).
22. Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S. Cognitive effects of hormonal therapy in early stage breast cancer patients: A prospective study. Psychooncology 18(8), 811-821 (2009).
23. Loehberg CR, Jud SM, Haeberle L et al. Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial. Breast Cancer Res. Treat. 121(1), 101-110 (2010).
24. Dunn BK, Ryan A. Phase 3 trials of aromatase inhibitors for breast cancer prevention: Following in the path of the selective estrogen receptor modulators. Ann. NY Acad. Sci. 1155, 141-161 (2009).
25. Goss PE, Ingle JN, Ales-Martinez JE et al. Exemestane for breast-cancer prevention in postmenopausal women. N. Engl. J. Med. 364(25), 2381-2391 (2011). Prospective, chemopreventive aromatase inhibitor study in patients at increased risk for breast cancer that showed decreased invasive breast cancer incidence with exemestane use.
26. Phillips KA, Ribi K, Fisher R. Do aromatase inhibitors have adverse effects on cognitive function? Breast Cancer Res. 13(1), 203 (2011).